Aggressive T-Cell Non-Hodgkin Lymphoma — Trials

Aggressive T-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

289 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 62
Recruiting: 32
Ph III recruiting: 3
Growth YoY: —
Industry share: 21%
Top sponsor: City of Hope Medical Center
Termination share: 33%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (47)

clinicaltrialsPublishedShowing 1–50 of 56 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05254899	A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102)(CLCG-2102)	completed	Phase 2	54	Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER	1	Aug 20, 2026	clinicaltrials
NCT02223208	Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas(FIL_PTCL13)	completed	Phase 1 / Phase 2	89	Fondazione Italiana Linfomi - ETS